These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 26953900)

  • 1. In vivo heat inactivation of serum can distinguish false positive cross matches in renal transplants.
    Riley AA; Klingman L; Brier ME; Chand DH
    Int J Artif Organs; 2016 Feb; 39(2):63-7. PubMed ID: 26953900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
    Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
    Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival.
    Lentine KL; Graff RJ; Xiao H; Modanlou KA; Salvalaggio PR; Brennan DC; Pinsky BW; Burroughs TE; Schnitzler MA
    Clin Transpl; 2008; ():253-66. PubMed ID: 19708460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype.
    Bryan CF; Martinez J; Muruve N; Nelson PW; Pierce GE; Ross G; Shield CF; Warady BA; Aeder MI; Harrell KM; Helling TS; Luger AM
    Clin Transplant; 2001; 15 Suppl 6():28-35. PubMed ID: 11903383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight years of outcomes of the Dutch Living Donor Kidney Exchange Program.
    de Klerk M; Kal-van Gestel JA; Haase-Kromwijk BJ; Claas FH; Weimar W;
    Clin Transpl; 2011; ():287-90. PubMed ID: 22755421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat inactivation can differentiate between IgG and IgM antibodies in the pretransplant cross match.
    Al-Muzairai IA; Mansour M; Almajed L; Alkanderi N; Alshatti N; Samhan M
    Transplant Proc; 2008 Sep; 40(7):2198-9. PubMed ID: 18790190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts.
    Daniel V; Sadeghi M; Suesal C; Scherer S; Tran H; Gombos P; Trojan K; Morath C; Opelz G
    Clin Transplant; 2016 Feb; 30(2):124-30. PubMed ID: 26537026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.
    Billen EV; Christiaans MH; van den Berg-Loonen EM
    Tissue Antigens; 2009 Sep; 74(3):205-12. PubMed ID: 19497037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
    Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
    Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of living donor renal transplants with a negative cross-match and pretransplant donor-specific antibody.
    Knight RJ; Devos JM; Patel SJ; Land G; Moore LW; Gaber L; Gaber AO
    Transplant Proc; 2013 May; 45(4):1399-401. PubMed ID: 23726582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The UNOS Scientific Renal Transplant Registry.
    Cecka JM
    Clin Transpl; 1999; ():1-21. PubMed ID: 11038622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation with positive complement-dependent microcytotoxicity crossmatch in contemporary kidney transplantation: Practice patterns and associated outcomes.
    Graff RJ; Xiao H; Duffy B; Schnitzler MA; Axelrod D; Lentine KL
    Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):234-45. PubMed ID: 22382213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined liver-kidney transplantation in patients with cirrhosis and renal failure: effect of a positive cross-match and benefits of combined transplantation.
    Morrissey PE; Gordon F; Shaffer D; Madras PN; Silva P; Sahyoun AI; Monaco AP; Hill T; Lewis WD; Jenkins RL
    Liver Transpl Surg; 1998 Sep; 4(5):363-9. PubMed ID: 9724473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique molecular changes in kidney allografts after simultaneous liver-kidney compared with solitary kidney transplantation.
    Taner T; Park WD; Stegall MD
    Kidney Int; 2017 May; 91(5):1193-1202. PubMed ID: 28233612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney transplantation in the United States.
    Cecka JM
    Clin Transpl; 2008; ():1-18. PubMed ID: 19711510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants.
    Goh A; Oei E; Vathsala A
    Transplant Proc; 2012 Jan; 44(1):193-9. PubMed ID: 22310613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The UNOS Scientific Renal Transplant Registry--ten years of kidney transplants.
    Cecka JM
    Clin Transpl; 1997; ():1-14. PubMed ID: 9919387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera. Race, transplant history, and HLA-DR1 phenotype.
    Barger B; Shroyer TW; Hudson SL; Deierhoi MH; Barber WH; Curtis JJ; Julian BA; Luke RG; Diethelm AG
    Transplantation; 1989 Feb; 47(2):240-5. PubMed ID: 2645705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.